🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. RO7790121, RO7790121 placebo/diluent

    Hoffmann-La Roche

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  2. RTP-026 Placebo, RTP-026

    Lacuna Pharma Pty Ltd

    Patients with ST-Elevation Myocardial Infarction (STEMI)

    phase 2 small molecule active

    1 trial

  3. Radotinib HCl, Placebo for Radotinib HCl

    Alphapharm Pty Ltd

    Treatment of Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  4. Ramelteon and Placebo (25 possible combinations total)

    Takeda

    Chronic Insomnia

    phase 2 small molecule completed

    1 trial

  5. Ramelteon or Placebo

    Takeda

    Sleep Apnea, Obstructive

    phase 2 small molecule completed

    1 trial

  6. Ramelteon, triazolam, and placebo (56 possible combinations total)

    Takeda

    Drug Abuse

    phase 2 small molecule completed

    1 trial

  7. Reparixin, Placebo - Tablet for oral use

    Dompe' Farmaceutici S.p.A.

    Acute Respiratory Distress Syndrome

    phase 2 small molecule active

    1 trial

  8. Rifamycin SV sodium in situ gelling solution matching placebo (80 mL) for rectal administration, Rifamycin 1% in situ gelling solution (80 mL) for rectal administration

    Cosmo Technologies Ltd

    patients with mild to moderate left-sided ulcerative colitis

    phase 2 small molecule active

    1 trial

  9. Riociguat Bayer, Riociguat Bayer, Placebo for riociguat, Riociguat Bayer

    Bayer AG

    Patients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD)

    phase 2 small molecule active

    1 trial

  10. Ritlecitinib Tosilate, Placebo for pf-06651600-15

    Pfizer Australia Pty Ltd

    HIDRADENITIS SUPPURATIVA

    phase 2 small molecule active

    1 trial

  11. Ritlecitinib tosilate, Placebo for pf-06651600-15, 100 mg, Placebo for pf-06651600-15, 50 mg, LORATADINE, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    CHRONIC SPONTANEOUS URTICARIA

    phase 2 small molecule active

    1 trial

  12. S-606001 matching placebo, S-606001

    Shionogi B.V.

    Late-onset Pompe disease.

    phase 2 small molecule active

    1 trial

  13. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  14. SALBUTAMOL, FLUTICASONE PROPIONATE, NVA237, NVA237, SALMETEROL XINAFOATE, The Placebo is a generic Placebo, inhalation powder, hard capsule. It is used to match an active dosage forms (NVA237 12.5µg and NVA 237 25µg) in this clinical trial. The placebo comprises inactive excipients (magnesium stearate and lactose monohydrate) encapsulated in hard non-gelatin capsules matching those used for the active drug product.

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule active

    1 trial

  15. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  16. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  17. SAR443765 / LUNSEKIMIG, Matched Placebo to Test, MOMETASONE

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  18. SAR444656, Matched Placebo

    Sanofi-aventis Healthcare Pty Ltd

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  19. SCD-044 Tablets 0.1mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 0.3mg, SCD-044 Tablets 1.0mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    atopic dermatitis

    phase 2 small molecule active

    1 trial

  20. SCD-044 Tablets 0.3mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 1.0mg, SCD-044 Tablets 0.1mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    moderate to severe plaque psoriasis

    phase 2 small molecule active

    1 trial

  21. SODIUM CHLORIDE, ADALIMUMAB, LAD191, LAD191 placebo

    Almirall, S.A.

    Moderate-to-severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  22. SPYPBO-101 Placebo to SPY072, SPY072

    Spyre Therapeutics

    Moderately to Severely Active Rheumatologic Disease

    phase 2 small molecule active

    1 trial

  23. STN1010904, Placebo (vehicle), STN1010904

    Santen Oy

    Fuchs Endothelial Corneal Dystrophy (FECD)

    phase 2 small molecule active

    1 trial

  24. SUB01423MIG, SUB01423MIG, Colesevelam-matching placebo film-coated oral tablets (Unit Dose C)., Colesevelam-matching placebo film-coated oral tablets (Unit Dose D)., DISSENTEN 2 mg compresse

    Monte Rosa Therapeutics

    Bile acid diarrhoea

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources